Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIDEVOL: Clofarabine in High-Risk MDS After Azacitidine Failure
NCT01063257Phase 2Completed
- Sponsor
- Groupe Français des Myélodysplasies
- Start
- Apr 2010
- Primary completion
- Mar 2014
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of clofarabine in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), acute myeloid leukemia (AML), sponsored by Groupe Français des Myélodysplasies. Started Apr 2010; status: completed.
02
Drugs
clofarabine
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01063257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01063257.